Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40632 | 0.90 | — | — | |
| SCHEMBL29142535 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL28508743 | 0.87 | — | — | |
| SCHEMBL6606391 | 0.87 | — | — | |
| SCHEMBL11165087 | 0.83 | CYP1A2 (0.73) | CYP1A2LMNACYP2A6AHRALOX5 | |
| SCHEMBL28215 | 0.83 | CYP1A2 (0.73) | CYP1A2LMNACYP2A6AHRALOX5 | |
| SCHEMBL3952742 | 0.83 | CYP1A2 (0.73) | CYP1A2LMNACYP2A6AHRALOX5 | |
| SCHEMBL25437316 | 0.79 | CYP1A2 (0.69) | CYP1A2LMNACYP2A6AHRALOX5 | |
| Hydrogen Sulfide SCHEMBL10394839 | 0.79 | CYP1A2 (0.69) | CYP1A2LMNACYP2A6AHRALOX5 | |
| Ethyne SCHEMBL29216096 | 0.76 | CYP1A2 (0.65) | CYP1A2LMNACYP2A6AHRALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| CN-102690330-A | Tri-substituted glycopeptide derivative and pharmaceutical composition, and preparation method and purpose thereof | ZHEJIANG MED XINCHANG PHARM | 2012-09-26 | — | — | CN | claimed |
| CN-102690331-A | Monosaccharide glycopeptide derivative, pharmaceutical composition, preparation method and purpose thereof and preparation method of intermediate | ZHEJIANG MED XINCHANG PHARM | 2012-09-26 | — | — | CN | claimed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | claimed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | claimed |
| US-7521418-B2 | When used in combination with glycopeptide antibacterial agent, the amount of polyene macrolide antifungal agent needed to treat a fungal infection is reduced thereby resulting in fewer side effects | THERAVANCE, INC. (US) | 2009-04-21 | — | — | US | claimed |
| CN-100463917-C | Reductive alkylation of glycopeptide antibiotics | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | claimed |
| US-7351691-B2 | Bactericides with antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals | THERAVANCE, INC. (US) | 2008-04-01 | — | — | US | claimed |
| EP-1292611-B1 | GLYCOPEPTIDE CARBOXY-SACCHARIDE DERIVATIVES | THERAVANCE INC (US) | 2008-03-12 | — | — | EP | claimed |
| WO-1999010006-A1 | THERAPY FOR STAPHYLOCOCCUS AUREUS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| EP-0881229-A2 | Alkylated antibiotic hexapeptides | ELI LILLY AND COMPANY (US) | 1998-12-02 | — | — | EP | claimed |
| EP-0881230-A2 | Urea and thiourea derivatives of antibiotic glycopeptides | ELI LILLY AND COMPANY (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1998052589-A1 | ALKYLATED HEXAPEPTIDES | ELI LILLY AND COMPANY (US) | 1998-11-26 | — | — | WO | claimed |
| WO-1998052592-A1 | UREA AND THIOUREA DERIVATIVES OF GLYCOPEPTIDES | ELI LILLY AND COMPANY (US) | 1998-11-26 | — | — | WO | claimed |
| WO-1998052596-A1 | GLYCOPEPTIDE HEXAPEPTIDES | ELI LILLY AND COMPANY (US) | 1998-11-26 | — | — | WO | claimed |
| EP-0879825-A2 | Derivatives of antibibioc A82846B(Chloroorienticin A) | ELI LILLY AND COMPANY (US) | 1998-11-25 | — | — | EP | claimed |
| WO-1998000153-A1 | AMIDES | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | claimed |
| EP-0816378-A1 | Glycopeptide antibiotic amide derivatives | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| EP-0009306-B1 | ANTI-ARTHRITIC HYDROXYACETIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND PROCESSES FOR THEIR MANUFACTURE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-11-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | CYP1A2 1481/4885LMNA 2873/4885CYP2A6 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.